Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome

Li,Pei; Wang,Sujie; Zhang,Ruili; Pei,Jian; Chen,Lili; Cao,Yibin; Zhang,Haoliang; Yang,Guofeng

doi:10.3892/etm.2018.6117

June-2018 Volume 15 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2018 Volume 15 Issue 6

Full Size Image

Article Open Access

Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome

Authors:
- Pei Li
- Sujie Wang
- Ruili Zhang
- Jian Pei
- Lili Chen
- Yibin Cao
- Haoliang Zhang
- Guofeng Yang
View Affiliations / Copyright

Affiliations: Department of Neurology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Neurology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Neurology, Zunhua People's Hospital, Tangshan, Hebei 064200, P.R. China, Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Radiotherapy and Chemotherapy, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 5177-5182
|
Published online on: May 2, 2018

https://doi.org/10.3892/etm.2018.6117
Expand metrics +

Abstract

The purpose of the present study was to screen for differentially expressed proteins in the cerebrospinal fluid (CSF) of patients with Guillain‑Barré syndrome (GBS). The identification of differentially expressed protein can provide new targets for understanding the pathogenic mechanism, early clinical diagnosis, prognosis and for measuring the effectiveness of interventions. We enrolled 50 GBS patients and 50 meningitis patients (control group) to compare protein expression in CSF. The GBS cases included 28 cases of acute inflammatory demyelinating polyneuropathy (AIDP) and 22 cases of acute motor axonal neuropathy (AMAN). We then performed two‑dimensional differential in‑gel electrophoresis combined with matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry to identify the differentially expressed proteins. The expression levels were validated by ELISA, and their accuracy, sensitivity, and specificity in GBS diagnosis were analyzed by the receiver operating characteristic curve. Three differentially expressed proteins were identified, including the upregulated haptoglobin (Hp) and heat shock protein 70 (Hsp70), and downregulated cystatin C. There were no significant differences between the AIDP and AMAN patients in the positive rates and quantitative expression levels of the three differentially expressed proteins. The accuracy of Hp in the diagnosis of GBS was 0.835, sensitivity was 86.7%, and specificity was 88.2%. The accuracy of cystatin C in the diagnosis of GBS was 0.827, sensitivity was 85.5%, and specificity was 89.7%. The accuracy of Hsp70 in the diagnosis of GBS was 0.841, its sensitivity was 87.8%, and its specificity was 92.3%. Hp and Hsp70 are significantly increased, and cystatin C is downregulated in CSF of GBS patients, which provides important biomarkers for early GBS diagnosis, although these proteins cannot distinguish AIDP and AMAN.

View Figures

View References

1	Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P and Willison HJ: Inhibition of complement in Guillain-Barré syndrome: The ICA-GBS study. J Peripher Nerv Syst. 1:4–12. 2017. View Article : Google Scholar
2	Uncini A, Shahrizaila N and Kuwabara S: Zika virus infection and Guillain-Barré syndrome: A review focused on clinical and electrophysiological subtypes. J Neurol Neurosurg Psychiatry. 88:266–271. 2017. View Article : Google Scholar : PubMed/NCBI
3	Hughes RA, Brassington R, Gunn AA and van Doorn PA: Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 10:CD0014462016.PubMed/NCBI
4	Ding Y, Han R, Jiang W, Xiao J, Liu H, Chen X, Li X and Hao J: Programmed death ligand 1 plays a neuroprotective role in experimental autoimmune neuritis by controlling peripheral nervous system inflammation of rats. J Immunol. 197:3831–3840. 2016. View Article : Google Scholar : PubMed/NCBI
5	Halstead SK, Kalna G, Islam MB, Jahan I, Mohammad QD, Jacobs BC, Endtz HP, Islam Z and Willison HJ: Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes. Neurol Neuroimmunol Neuroinflamm. 3:e2842016. View Article : Google Scholar : PubMed/NCBI
6	Heywood WE, Baud A, Bliss E, Sirka E, Schott JM, Zetterberg H, Galimberti D, Sebire NJ and Mills K: A high throughput, multiplexed and targeted proteomic CSF assay to quantify neurodegenerative biomarkers and apolipoprotein E isoforms status. J Vis Exp. 116:1156–1157. 2016.
7	Štěpánová S and Kašička V: Analysis of proteins and peptides by electromigration methods in microchips. J Sep Sci. 40:228–250. 2017. View Article : Google Scholar : PubMed/NCBI
8	Goldman AS, Schmalstieg EJ, Dreyer CF, Schmalstieg FC Jr and Goldman DA: Franklin Delano Roosevelt's (FDR's) (1882–1945) 1921 neurological disease revisited; the most likely diagnosis remains Guillain-Barré syndrome. J Med Biogr. 24:452–459. 2016. View Article : Google Scholar : PubMed/NCBI
9	Papathanasiou A and Markakis I: Clinical heterogeneity of Guillain-Barré syndrome in the emergency department: Impact on clinical outcome. Case Rep Emerg Med. 2016:49812742016.PubMed/NCBI
10	Zhang HL, Zhang XM, Mao XJ, Deng H, Li HF, Press R, Fredrikson S and Zhu J: Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurol Scand. 125:129–135. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chang KH, Lyu RK, Tseng MY, Ro LS, Wu YR, Chang HS, Hsu WC, Kuo HC, Huang CC, Chu CC, et al: Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. Proteomics Clin Appl. 1:467–475. 2007. View Article : Google Scholar : PubMed/NCBI
12	Jin T, Hu LS, Chang M, Wu J, Winblad B and Zhu J: Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol. 14:563–568. 2007. View Article : Google Scholar : PubMed/NCBI
13	Romi F, Helgeland G and Gilhus NE: Heat-shock proteins in clinical neurology. Eur Neurol. 66:65–69. 2011. View Article : Google Scholar : PubMed/NCBI
14	Brettschneider J, Petzold A, Süssmuth S and Tumani H: Cere-brospinal fluid biomarkers in Guillain-Barré syndrome - where do we stand? J Neurol. 256:3–12. 2009. View Article : Google Scholar : PubMed/NCBI
15	Snorradottir AO, Isaksson HJ, Kaeser SA, Skodras AA, Olafsson E, Palsdottir A and Bragason BT: Deposition of collagen IV and aggrecan in leptomeningeal arteries of hereditary brain haemorrhage with amyloidosis. Brain Res. 1535:106–114. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kaur G and Levy E: Cystatin C in Alzheimer's disease. Front Mol Neurosci. 5:792012. View Article : Google Scholar : PubMed/NCBI
17	Yang Y, Liu S, Qin Z, Cui Y, Qin Y and Bai S: Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barré Syndrome by a proteomical approach. Mol Biol Rep. 36:677–682. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles